Artificial intelligence in ovarian cancer prevention and control: a brief review of detection, treatment, and equity (2021–2026)
Zhenyu Huang, Boyang Wei, Ying Shen · 2026
Read Artificial intelligence in ovarian cancer prevention and control: a brief review of detection, treatment, and equity (2021–2026) by Zhenyu Huang, Boyang Wei, Ying Shen (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13581674.txt.
Description
Zhenyu Huang, Boyang Wei, and Ying Shen review AI for ovarian cancer care from 2021 to 2026, with an eye on fairness. Their 2026 mini review starts from a hard fact: the cancer kills widely because early signs are vague and screening is weak. Unequal access to tests also shapes outcomes.
In detection, models blend blood panels, routine labs, ultrasound, and DNA signals to beat the classic single marker. Most still await forward-looking validation, though. In care, image, tissue, and gene models predict drug response and survival, yet few run in real clinics. Blood, lab, and ultrasound tools sit closest to workflow trials. The authors urge multi-center forward studies and equity checks before wider rollout.
Catalog record
| CREATOR | Zhenyu Huang, Boyang Wei, Ying Shen |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 33 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |